Leerink Partnrs Predicts Weaker Earnings for Exact Sciences

Key Points

• Leerink Partners has revised its Q3 2025 earnings estimate for Exact Sciences down to $0.15 per share, from a previously forecasted $0.16.
• The company reported a revenue increase of 16.0% year-over-year, with Q2 earnings per share of $0.22 exceeding analysts' expectations by $0.24.
• Exact Sciences' consensus rating is a "Moderate Buy" with an average target price of $69.19, following various updates from analysts including price target adjustments by Cowen and Royal Bank of Canada.

Exact Sciences Corporation (NASDAQ:EXAS - Free Report) - Equities research analysts at Leerink Partnrs cut their Q3 2025 earnings estimates for Exact Sciences in a note issued to investors on Friday, October 17th. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings of $0.15 per share for the quarter, down from their prior forecast of $0.16. The consensus estimate for Exact Sciences' current full-year earnings is ($0.58) per share. Leerink Partnrs also issued estimates for Exact Sciences' FY2025 earnings at $0.47 EPS and Q3 2026 earnings at $0.32 EPS.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The medical research company reported $0.22 earnings per share for the quarter, topping analysts' consensus estimates of ($0.02) by $0.24. Exact Sciences had a negative net margin of 34.19% and a negative return on equity of 1.75%. The company had revenue of $811.09 million for the quarter, compared to analysts' expectations of $774.43 million. During the same quarter last year, the company earned ($0.09) earnings per share. The firm's revenue for the quarter was up 16.0% on a year-over-year basis.

EXAS has been the topic of a number of other reports. Cowen reaffirmed a "buy" rating on shares of Exact Sciences in a report on Thursday, August 7th. Royal Bank Of Canada lowered their price objective on shares of Exact Sciences from $54.00 to $46.00 and set a "sector perform" rating on the stock in a research report on Thursday, August 7th. UBS Group lowered their price objective on shares of Exact Sciences from $61.00 to $53.00 and set a "neutral" rating on the stock in a research report on Thursday, August 7th. Wells Fargo & Company set a $68.00 price objective on shares of Exact Sciences in a research report on Wednesday, October 1st. Finally, Craig Hallum lifted their price objective on shares of Exact Sciences from $65.00 to $85.00 and gave the company a "buy" rating in a research report on Thursday, September 11th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $69.19.

Exact Sciences Stock Performance

Shares of Exact Sciences stock opened at $61.23 on Monday. The firm's fifty day simple moving average is $52.24 and its 200-day simple moving average is $51.16. The stock has a market capitalization of $11.59 billion, a price-to-earnings ratio of -11.28, a PEG ratio of 5.43 and a beta of 1.24. Exact Sciences has a 12 month low of $38.81 and a 12 month high of $72.83. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.89 and a quick ratio of 2.56.

Insider Activity at Exact Sciences

In other Exact Sciences news, Director James Edward Doyle sold 2,000 shares of the business's stock in a transaction on Thursday, October 9th. The shares were sold at an average price of $60.00, for a total transaction of $120,000.00. Following the sale, the director directly owned 57,962 shares in the company, valued at approximately $3,477,720. The trade was a 3.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.20% of the company's stock.

Institutional Investors Weigh In On Exact Sciences

Several institutional investors have recently made changes to their positions in EXAS. Great Lakes Advisors LLC boosted its position in shares of Exact Sciences by 3.7% in the 1st quarter. Great Lakes Advisors LLC now owns 4,971 shares of the medical research company's stock worth $215,000 after buying an additional 178 shares in the last quarter. Capital Asset Advisory Services LLC boosted its position in shares of Exact Sciences by 4.8% in the 3rd quarter. Capital Asset Advisory Services LLC now owns 3,941 shares of the medical research company's stock worth $216,000 after buying an additional 182 shares in the last quarter. Nissay Asset Management Corp Japan ADV boosted its position in shares of Exact Sciences by 0.8% in the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 22,432 shares of the medical research company's stock worth $971,000 after buying an additional 187 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its position in shares of Exact Sciences by 0.4% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 58,333 shares of the medical research company's stock worth $3,127,000 after buying an additional 217 shares in the last quarter. Finally, OneDigital Investment Advisors LLC boosted its position in shares of Exact Sciences by 0.3% in the 1st quarter. OneDigital Investment Advisors LLC now owns 100,872 shares of the medical research company's stock worth $4,367,000 after buying an additional 270 shares in the last quarter. 88.82% of the stock is currently owned by hedge funds and other institutional investors.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.